2026 年 1 月
中国普通外科杂志 Vol.35 No.1第 35 卷 第 1 期
China Journal of General Surgery Jan. 2026
http://www.zpwz.net
肝细胞癌术后辅助治疗专家共识 （2026版）
肝癌术后辅助治疗中国专家共识协作组；中国医师协会外科医师分会；中国抗癌协会肝癌专业委员会；
中华医学会肿瘤学分会肝癌学组
摘 要 肝细胞癌 （以下简称肝癌） 术后复发转移是影响患者长期生存的重要因素，目前尚无公认的有效预防
术后复发转移的辅助治疗方案。以靶向药物、免疫检查点抑制剂为代表的系统抗肿瘤治疗和局部治疗
单独或联合应用的辅助治疗策略正在积极探索中。肝癌术后辅助治疗中国专家共识协作组、中国医师
协会外科医师分会、中国抗癌协会肝癌专业委员会、中华医学会肿瘤学分会肝癌学组组织相关领域专
家，基于新的循证医学证据，经过多次讨论、反复修订，最终更新形成 《肝细胞癌术后辅助治疗专家
共识 （2026版）》，旨在梳理肝癌术后辅助治疗相关证据，结合临床实践，为临床医师开展术后辅助
治疗提供更好指导，提高肝癌患者术后生存获益。
关键词 癌，肝细胞；肝切除术；辅助治疗；专家共识
中图分类号： R735.7
Expert consensus on postoperative adjuvant therapy for
hepatocellular carcinoma (2026 edition)
Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma;
Chinese College of Surgeons; Committee of Liver Cancer, Chinese Anti-Cancer Association; Liver Cancer
Group, Society of Oncology, Chinese Medical Association
Abstract Recurrence and metastasis after surgery remain major determinants of long-term survival in patients with
hepatocellular carcinoma (HCC), and to date, no universally accepted postoperative adjuvant therapy has
been established to effectively prevent recurrence. In recent years, postoperative adjuvant strategies
involving systemic antitumor therapies—represented by targeted agents and immune checkpoint
inhibitors—used alone or in combination with locoregional therapies have been actively explored. The
Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular
Carcinoma, together with the Chinese College of Surgeons, the Committee of Liver Cancer of the
Chinese Anti-Cancer Association, and the Liver Cancer Group of the Society of Oncology of the Chinese
Medical Association, convened experts from relevant disciplines to review and synthesize updated
evidence. Through multiple rounds of discussion and revision, the Expert consensus on postoperative
adjuvant therapy for hepatocellular carcinoma (2026 edition) was formulated. This consensus aims to
systematically summarize the available evidence on postoperative adjuvant therapy for HCC, integrate
current clinical practice, and provide practical guidance for clinicians, with the goal of improving
· 指南与共识 ·
doi:10.7659/j.issn.1005-6947.260017
http://dx.doi.org/10.7659/j.issn.1005-6947.260017
China Journal of General Surgery, 2026, 35(1):1- 20.
基金项目： 慢性非传染性疾病国家科技重大专项基金资助项目 （2024ZD0520400，2024ZD0520401）。
收稿日期： 2025-10-29； 修订日期： 2025-12-25。
通信作者：樊嘉，Email: fan.jia@zs-hospital.sh.cn
1
